Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PRX002 · 2 trials · 1 indication
maximum concentration (Cmax)
| Arm | Type | Description |
|---|---|---|
| PRX002 | EXPERIMENTAL | PRX002 |
| Placebo | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| PRX002 | DRUG | - |
| Placebo | OTHER | - |
Inclusion Criteria: * Idiopathic Parkinson's disease, Hoehn and Yahr 1-3 * Body weight range of ≥ 45kg/99 lbs to ≤ 110 kg/242 lbs * Female subjects must be surgically sterile or post-menopausal or if of child-bearing potential must use contraception * Male subjects and their partners of childbearin...
Top 15 of 23 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Supernus Pharmaceuticals, Inc. | SUPN | 2 | PHASE3 | Onapgo (SPN-830) |
| Prothena Corp. Plc | PRTA | 3 | PHASE3 | Prasinezumab |
| Denali Therapeutics Inc. | DNLI | 1 | PHASE2 | BIIB122 |
| Bayer | BAYRY | 4 | PHASE3 | bemdaneprocel, AB-1005 |
| Biohaven Ltd. | BHVN | 1 | PHASE2 | BHV-8000 |
| AC Immune SA | ACIU | 2 | PHASE2 | ACI-7104.056 |
| Eli Lilly and Company | LLY | 4 | PHASE1 | LY3884961, LY4006896, LY3962681 |
| Gain Therapeutics, Inc. | GANX | 2 | PHASE2 | GT-02287 |
| Annovis Bio Inc | ANVS | 1 | PHASE2 | Buntanetap |
| Regeneron Pharmaceuticals, Inc. | REGN | 2 | PHASE1 | ALN-SNCA |
| MeiraGTx Holdings Plc | MGTX | 1 | PHASE1 | AAV-GAD |
| Serina Therapeutics, Inc. | SER | 1 | PHASE1 | SER-252 |
| Ardelyx, Inc. | ARDX | 1 | PHASE2 | Tenapanor |
| Hoffmann-La Roche | RHHBY | 1 | PHASE1 | RO7568282 |
| Merck & Co., Inc. | MRK | 1 | EARLY_PHASE1 | MK-0947 |
PRX002 is an investigational monoclonal antibody being developed for the treatment of Parkinson's disease. It has been studied in Phase 1 clinical trials in both healthy volunteers and patients with Parkinson's disease. It is not approved for any indication and remains in clinical development.
PRX002 targets alpha-synuclein, a protein that aggregates in the brains of people with Parkinson's disease. By binding to alpha-synuclein, the antibody is designed to interfere with the spread of the pathological form of the protein. Alpha-synuclein is the molecular target of PRX002.
PRX002 is being developed by Prothena Corporation plc, which trades on the Nasdaq under the ticker PRTA. Prothena is a clinical-stage neuroscience company focused on protein dysregulation diseases, and PRX002 is its monoclonal antibody candidate for Parkinson's disease.
PRX002 is in Phase 1 clinical development. Two Phase 1 trials have been completed, one single ascending dose study in healthy subjects and one multiple ascending dose study in patients with Parkinson's disease. The program has not advanced beyond Phase 1 based on the trials conducted to date.
PRX002 has been evaluated in two completed Phase 1 trials. NCT02095171 was a single ascending dose study in healthy subjects that enrolled 40 participants. NCT02157714 was a multiple ascending dose study in patients with Parkinson's disease that enrolled 64 participants. Both trials were conducted in the United States.
Both PRX002 trials were randomized, double-blind, and placebo-controlled Phase 1 studies. Together they enrolled 104 participants across healthy volunteers and patients with Parkinson's disease. The single ascending dose trial enrolled adults aged 21 and older, while the multiple ascending dose trial enrolled patients aged 40 and older.